Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
37
AKTX Quote, Financials, Valuation and Earnings
Last price:
$1.12
Seasonality move
:
22.09%
Day range:
$1.10 - $1.14
52-week range:
$0.85 - $4.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.67x
Volume:
9K
Avg. volume:
23.4K
1-year change:
-70.5%
Market cap:
$36.4M
Revenue:
--
EPS (TTM):
-$1.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
-- | -$0.12 | -- | -- | $7.00 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$11.1M | -$0.14 | -91.39% | -8.33% | $1.45 |
|
AUTL
Autolus Therapeutics PLC
|
$12.9M | -$0.23 | -80.39% | -10.73% | $9.86 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
DBVT
DBV Technologies SA
|
$747.8K | -$0.18 | -- | -84.24% | $16.06 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
$1.13 | $7.00 | $36.4M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.28 | $1.45 | $73.3M | -- | $0.00 | 0% | 0.40x |
|
AUTL
Autolus Therapeutics PLC
|
$2.44 | $9.86 | $649.4M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$0.84 | $17.94 | $4.2M | -- | $0.00 | 0% | 0.87x |
|
DBVT
DBV Technologies SA
|
$9.79 | $16.06 | $267.8M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $304.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
-- | -4.145 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.289 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.256 | -- | 8.74x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.010 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
-- | -2.552 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKTX
Akari Therapeutics PLC
|
-- | -$3.5M | -- | -- | -- | -$2.2M |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$26.6M | -- | -- | -- | -$19.7M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
Akari Therapeutics PLC vs. Competitors
-
Which has Higher Returns AKTX or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of -653.18%. Akari Therapeutics PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -- -- ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About AKTX or ADAP?
Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 519.47%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.45 which suggests that it could grow by 424.86%. Given that Akari Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Akari Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC1 0 0 ADAPAdaptimmune Therapeutics PLC2 4 0 -
Is AKTX or ADAP More Risky?
Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.923%.
-
Which is a Better Dividend Stock AKTX or ADAP?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or ADAP?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Akari Therapeutics PLC's net income of -$3.7M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 0.40x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$3.7M ADAPAdaptimmune Therapeutics PLC0.40x -- $7.3M -$47.6M
-
Which has Higher Returns AKTX or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of -781.13%. Akari Therapeutics PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -- -- AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About AKTX or AUTL?
Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 519.47%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 303.92%. Given that Akari Therapeutics PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Akari Therapeutics PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC1 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is AKTX or AUTL More Risky?
Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.
-
Which is a Better Dividend Stock AKTX or AUTL?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or AUTL?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Akari Therapeutics PLC's net income of -$3.7M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$3.7M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns AKTX or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -- -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About AKTX or BDRX?
Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 519.47%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Akari Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Akari Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC1 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is AKTX or BDRX More Risky?
Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.
-
Which is a Better Dividend Stock AKTX or BDRX?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or BDRX?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$3.7M BDRXBiodexa Pharmaceuticals PLC0.87x -- -- --
-
Which has Higher Returns AKTX or DBVT?
DBV Technologies SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -- -- DBVTDBV Technologies SA-- -$1.30 -- -
What do Analysts Say About AKTX or DBVT?
Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 519.47%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 64.81%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC1 0 0 DBVTDBV Technologies SA1 0 0 -
Is AKTX or DBVT More Risky?
Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.
-
Which is a Better Dividend Stock AKTX or DBVT?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or DBVT?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$3.7M DBVTDBV Technologies SA-- -- -- -$27.1M
-
Which has Higher Returns AKTX or NCNA?
NuCana PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKTXAkari Therapeutics PLC-- -- -- NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About AKTX or NCNA?
Akari Therapeutics PLC has a consensus price target of $7.00, signalling upside risk potential of 519.47%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than Akari Therapeutics PLC, analysts believe NuCana PLC is more attractive than Akari Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AKTXAkari Therapeutics PLC1 0 0 NCNANuCana PLC0 1 0 -
Is AKTX or NCNA More Risky?
Akari Therapeutics PLC has a beta of 0.211, which suggesting that the stock is 78.884% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock AKTX or NCNA?
Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKTX or NCNA?
Akari Therapeutics PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is lower than NuCana PLC's net income of -$3.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKTXAkari Therapeutics PLC-- -- -- -$3.7M NCNANuCana PLC-- -- -- -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
